Refractory Fibrolamellar Carcinoma
1 clinical trials · Condition
◉ Watch Refractory Fibrolamellar Carcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma (NCT06620302) | Children's Oncology Group | 2025-06-12 |
Track Refractory Fibrolamellar Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.